This topic contains a solution. Click here to go to the answer

Author Question: Organizations with a strategy of unrelated diversification are likely to use a conglomerate ... (Read 98 times)

silviawilliams41

  • Hero Member
  • *****
  • Posts: 560
Organizations with a strategy of unrelated diversification are likely to use a conglomerate structure.
 
  Indicate whether the statement is true or false

Question 2

A population of organizations comprises the organizations that are going through the same stage of organizational life cycle at the same time.
 
  Indicate whether the statement is true or false



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

jamesnevil303

  • Sr. Member
  • ****
  • Posts: 337
Answer to Question 1

TRUE

Answer to Question 2

FALSE




silviawilliams41

  • Member
  • Posts: 560
Reply 2 on: Jul 7, 2018
YES! Correct, THANKS for helping me on my review


kjohnson

  • Member
  • Posts: 330
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

The immune system needs 9.5 hours of sleep in total darkness to recharge completely.

Did you know?

It is believed that humans initially contracted crabs from gorillas about 3 million years ago from either sleeping in gorilla nests or eating the apes.

Did you know?

Chronic marijuana use can damage the white blood cells and reduce the immune system's ability to respond to disease by as much as 40%. Without a strong immune system, the body is vulnerable to all kinds of degenerative and infectious diseases.

Did you know?

A serious new warning has been established for pregnant women against taking ACE inhibitors during pregnancy. In the study, the risk of major birth defects in children whose mothers took ACE inhibitors during the first trimester was nearly three times higher than in children whose mothers didn't take ACE inhibitors. Physicians can prescribe alternative medications for pregnant women who have symptoms of high blood pressure.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library